Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): An update on a previous case report

Clinical Pharmacology: Advances and Applications

Volumn 3, Issue 1, 2011, Pages 45-50

  Ohanian, Maro ^a   Cable, Christian ^a   Halka, Kathleen ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

aHUS; Atypical hemolytic uremic syndrome; Eculizumab; Thrombotic microangiopathy

Indexed keywords

CIPROFLOXACIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; ECULIZUMAB;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CASE REPORT; COLON RESECTION; CONTINUOUS HEMODIALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFECTION RISK; KIDNEY FUNCTION; LONG TERM CARE; MAINTENANCE THERAPY; MENINGOCOCCEMIA; MICROTHROMBUS; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; SEPSIS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 81255195666     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/cpaa.s23687     Document Type: Article

References (25)

1. Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009;4(8):1312-1316.
2. Châtelet V, Lobbedez T, Frémeaux-Bacchi V, Ficheux M, Ryckelynck JP, Hurault de LB. Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic- uremic syndrome: case report. Transplant Proc. 2010;42(10): 4353-4355.
3. Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Frémeaux-Bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol. 2011;7(1):23-35.
4. Nurnberger J, Phillip T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med. 2009;360(5):542-544.
5. Châtelet V, Frémeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de LB. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant. 2009;9(11):2644-2645.
6. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolyticuremic syndrome. N Engl J Med. 2009;360(5):544-546.
7. Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis. 2010;55(44):708-711.
8. Zimmerhackl LB, Hofer J, Cortina G, et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med. 2010;362(18):1746-1748.
9. Ardissino G, Testa S, Paglialonga F, et al. Remission of plasma-resistant atypical hemolytic uremic syndrome relapse on kidney graft with eculizumab. Presented at the 2nd International Conference on HUSMPGN- PNH; June 13-15, 2010; Innsbruck, Austria. p. 17.
10. Haffner H, Hofer J, Zimmerhackl LB, Pohl M. Effective eculizumab therapy of familiar atypical HUS in a 4 year old patient. Presented at the 2nd International Conference on HUS-MPGN-PNH; 2010 June 13-15; Innsbruck, Austria. p. 21.
11. Lapayraque AL, Phan V, Clermont MJ, et al. Effectiveness of eculizumab in a plasma infusion dependent patient with atypical haemolytic and uremic syndrome (a HUS) associated with heterozygous combined de Novo mutation in factor H gene. Presented at the 2nd International Conference on HUS-MPGN-PNH; June 13-15, 2010; Innsbruck, Austria. p. 24.
12. Tschumi S, Bucher BS, Sparta G, et al. Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings. Presented at the 2nd International Conference on HUS-MPGN-PNH; June 13-15, 2010; Innsbruck, Austria. p. 44.
13. Larrea CF, Cofan F, Oppenheimer F, Campistol JM, Escolar G, Lozano M. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation. 2010;89(7):903-904.
14. Legault DJ, Boelkins MR. Successful treatment of aHUS recurrence and arrest of plasma exchange resistant TMA post-renal transplantation with the terminal complement inhibitor eculizumab. Presented at the 51st ASH Annual meeting; December 6, 2009; Grand Rapids, MI. p. 2421.
15. Dmytrijuk A, Robie-Suh K, Cohen MH, Rieves D, Weiss K, Pazdur R. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist. 2008;13(9):993-1000.
16. Ohanian M, Cable C, Halka K. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clinical Pharmacology: Advances and Applications. doi: 10.2147/CPAA.S17904.
17. Alexion Pharmaceuticals. Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2009. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00838513?term=;NCT00838513&rank=1. Accessed on October 5, 2011. NLM identifier: NCT00838513.
18. Muus P, Legendre C, Douglas K, Hourmant M, Delmas Y, Herthelius B, et al. Safety and Efficacy of Eculizumab in aHUS Patients on Chronic Plasma Therapy: Interim Analysis from a Phase II Trial [abstract]. Presented at American Society of Nephrology Meeting, Renal Week 2010, Denver, CO. Available at: http://www.abstracts2view.com/asn10/view.php?nu=ASN10L1_1338a. Accessed on October 5, 2011.
19. Noris M, Remuzzi G. Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. Semin Nephrol. 2010; 30(4):395-408.
20. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676-1687.
21. GeneTests [homepage]. Available at: http://www.ncbi.nlm.nih.gov/sites/GeneTests. Accessed on October 5, 2011.
22. Molecular Otolaryngology and Renal Research Laboratories [homepage]. Available at: http://www.healthcare.uiowa.edu/labs/morl/THBD.htm. Accessed on October 5, 2011.
23. Zipfel PF, Edey M, Heinen S, et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 2007;3(3):e41.
24. Skerka C, Józsi M, Zipfel PF, Dragon-Durey MA, Frémeaux-Bacchi V. Autoantibodies in haemolytic uraemic syndrome (HUS). Thromb Haemost. 2009;101(2):227-232.
25. Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(4): 345-357.